Status:
COMPLETED
Study Evaluating Refacto For Pharmacovigilance
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Hemophilia A
Eligibility:
MALE
Brief Summary
The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.
Detailed Description
Non-interventional study: subjects to be selected according to the usual clinical practice of their physician
Eligibility Criteria
Inclusion
- Proven diagnosis of Hemophilia A
Exclusion
- Contraindications according to Summary of Product Characteristics
Key Trial Info
Start Date :
July 1 1999
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
288 Patients enrolled
Trial Details
Trial ID
NCT00195442
Start Date
July 1 1999
End Date
January 1 2010
Last Update
February 11 2011
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Vienna, Vienna, Austria, A-1090
2
Pfizer Investigational Site
Berlin, Germany, Germany, 10249
3
Pfizer Investigational Site
Wiesbaden, Germany, Germany, 65191
4
Pfizer Investigational Site
Frankfurt am Main, Hesse, Germany, 60596